Activated neutrophils are involved in a number of chronic inflammatory conditions, including RA and neuroinflammatory diseases, such as Alzheimer’s.
Based this in-vitro research, and on human anecdotal reports, there is evidence to support the use of APPA in other indications, all of which are in areas of high unmet need.
In-vitro work is currently underway investigating APPA’s role in the treament of Scleroderma, a rare connective tissue disease.
APPA is being considered for the treatment of Alzheimer’s disease where there is an increasing view that inflammation plays a pivotal role in the development of the disease.
Other diseases linked to inflammation are also being investigated, including Rheumatoid Arthritis (RA). APPA has been shown to moderate several activated neutrophil functions so has the potential to be a future treatment for RA and a number of other autoimmune diseases.